# OnCo record inaticabtagene-autoleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/inaticabtagene-autoleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "inaticabtagene-autoleucel" ;
  schema:name "Inaticabtagene autoleucel"@en ;
  schema:description "Inati-cel is a Chinese CAR-T for adults with acute lymphoblastic leukaemia that has come back or stopped responding, approved in 2023."@en ;
  schema:url <https://onco.cc/drugs/inaticabtagene-autoleucel/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.juventas.cn/>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Cell therapy (autologous CD19 CAR-T)" ;
  schema:alternateName "Yuanruida" ;
  onco:approval "China 2023: Adult relapsed or refractory CD19-positive B-cell acute lymphoblastic leukaemia" ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:companies <https://onco.cc/companies/juventas-cell-therapy/> ;
  onco:institutions <https://onco.cc/institutions/cams-hematology/> ;
  onco:trials <https://onco.cc/trials/nct05667506/>, <https://onco.cc/trials/nct04684147/>, <https://onco.cc/trials/nct04586478/> .